Your Investigational New Drug (IND) application is the official biography of your drug. It’s the complete story you tell the FDA to convince them your product is ready and reasonably safe for human testing. This story has several critical chapters: the Chemistry, Manufacturing, and Controls (CMC) section that details how your drug is made; the pharmacology and toxicology data from your preclinical studies; and the detailed clinical protocol outlining your plan for human trials. A successful submission weaves these elements into a clear and compelling narrative. This guide will show you how to structure that story, ensuring every section is robust, well-documented, and presented in a way that gives FDA reviewers confidence in your product and your plan.
Key Takeaways
- Structure your application for a smooth review. Your IND submission is your drug’s biography. Present a clear, complete story with well-organized manufacturing (CMC) data, preclinical results, and clinical protocols to avoid common documentation pitfalls.
- Make safety and compliance non-negotiable. The FDA’s review is centered on protecting trial participants. Prove your readiness with solid Good Manufacturing Practices (GMP), confirmed Institutional Review Board (IRB) approval, and thorough informed consent procedures.
- Engage with the FDA before you submit. A pre-IND meeting is your most valuable tool for preventing delays. Use this opportunity to get direct feedback and align on expectations, which can help you avoid a costly clinical hold down the line.
What Is an Investigational New Drug (IND) Application?
Think of an Investigational New Drug (IND) application as your formal request to the FDA for permission to start clinical trials—that is, to administer a new drug or biological product to people. It’s the critical bridge between preclinical research (like lab and animal studies) and human testing. This application is not just a formality; it’s a comprehensive dossier that demonstrates your product is reasonably safe to move forward.
Your submission must provide the FDA with enough information to make a thorough safety assessment. This includes your preclinical data on safety and efficacy, detailed manufacturing information, and the complete clinical trial protocol. Essentially, you’re showing the FDA that you’ve done your homework and have a solid plan to ensure the safety of trial participants and the integrity of the study.
Why an IND Application Matters
The primary goal of an IND application is to protect the people who volunteer for clinical trials. Before any new drug can be tested in humans, the FDA needs to be convinced that the study will be reasonably safe. The IND process serves as a crucial checkpoint, allowing regulators to review your findings from animal studies and your plans for human trials. This review helps ensure you’ve identified and mitigated potential risks.
Beyond safety, the IND allows you to begin gathering the data needed to prove your drug is both safe and effective for its intended use. By submitting a thorough Investigational New Drug (IND) Application, you’re not just following rules—you’re building a foundation of trust with regulators and protecting future patients.
When Do You Need to File an IND?
You need to file an IND application anytime you plan to conduct a clinical study of a new drug or biologic in humans, unless your study is specifically exempt. This applies whether you’re a commercial sponsor aiming to bring a product to market or an academic researcher studying an unapproved drug. The requirement ensures that any new therapeutic intervention undergoes a formal safety review before being administered to people.
Once you submit your application, a critical waiting period begins. The FDA has 30 calendar days to review your submission. If you don’t hear from the agency with an objection (a “clinical hold”) within those 30 days, your IND becomes effective, and you can officially begin your clinical trials. This 30-day clock makes careful preparation and a complete application absolutely essential to avoid delays.
The FDA’s Role in the Application Process
The FDA’s role is to act as a gatekeeper, ensuring that a proposed clinical trial doesn’t place human subjects at unreasonable risk. When a sponsor, typically the drug manufacturer, wants to test a new drug in humans, the FDA steps in to review the IND application. Agency reviewers with expertise in pharmacology, toxicology, chemistry, and medicine meticulously examine the preclinical data, manufacturing processes, and the proposed clinical protocol.
If the FDA identifies a problem—such as an unsafe study design or insufficient safety data—it can place the study on a “clinical hold.” This order stops the trial from starting until the sponsor addresses the agency’s concerns. The FDA’s active involvement throughout the development and approval process is designed to safeguard participants and ensure the scientific quality of the trial.
What Goes Into an IND Application?
Think of your Investigational New Drug (IND) application as a comprehensive biography of your new drug. It’s a detailed story you tell the FDA to demonstrate that your product is reasonably safe to be tested in humans. A complete and well-organized application is your best tool for a smooth review process. It requires pulling together extensive data from different stages of your product’s development, from its basic chemistry to pre-clinical safety studies. Each piece of information plays a critical role in building a convincing safety profile for your investigational drug.
Chemistry and Manufacturing Controls (CMC)
The CMC section is the foundation of your application, detailing the “what” and “how” of your drug product. You’ll need to provide in-depth information about the drug’s composition, its source, and how you manufacture it. This includes everything from the ingredients and their specifications to the entire production process. The FDA also needs to see data on the drug’s stability and the quality control measures you have in place. The goal is to prove you can produce a consistent, high-quality, and stable product for clinical trials, which is a core part of the Investigational New Drug application.
Pharmacology and Toxicology Data
This is where you present the results from your preclinical studies. Before you can test a drug in humans, you must establish its basic safety profile in animals. The pharmacology and toxicology data section summarizes these findings, showing the FDA what you’ve learned about the drug’s potential effects—both good and bad. These studies help determine a safe starting dose for human trials and identify potential risks to watch for. According to the National Institutes of Health, this data is essential for assessing whether the drug is safe enough to move forward into the clinical phase.
Clinical Protocols and Study Design
Here, you lay out your complete plan for the human trials. This section includes detailed clinical protocols that describe how the study will be conducted from start to finish. You’ll need to outline your objectives, the study design, and the number of participants. It also specifies how you will obtain informed consent from subjects and ensure their safety is monitored throughout the trial. A critical component is demonstrating that the study will be overseen by an Institutional Review Board (IRB), which is an independent committee that protects the rights and welfare of human research subjects.
Previous Human Experience
If your investigational drug has been tested in humans before, you must include that information here. This applies even if the studies were conducted in other countries or for different purposes. The FDA requires a complete picture of any prior human exposure to the drug to fully evaluate its safety profile. Providing a summary of this experience, including any adverse effects that were observed, helps the agency make a more informed decision about allowing your proposed clinical trials to proceed. Transparency is key, as this information contributes to the overall risk-benefit assessment.
Investigator Information
Your clinical trial is only as strong as the team running it. In this section, you need to provide information about the qualifications and experience of the investigators who will be conducting the study. This includes their CVs and a statement of their commitment to following the study protocol and FDA regulations. The FDA needs to be confident that the clinical investigators have the necessary expertise to conduct the trial safely and effectively. This helps build trust and assures the agency that the research will be managed by capable and responsible professionals.
Data Integrity Requirements
The credibility of your entire IND application rests on the quality and integrity of your data. Every piece of information you submit, from manufacturing details to toxicology reports, must be accurate, reliable, and thoroughly documented. The FDA has strict expectations for data integrity, and any inconsistencies or gaps can lead to significant delays or even a clinical hold on your study. As noted by industry experts, managing documentation is one of the biggest challenges in IND submissions. Establishing robust systems for data collection and management from the very beginning is crucial for a successful application.
What Are the Different Types of INDs?
An Investigational New Drug (IND) application isn’t a one-size-fits-all document. The type you submit to the FDA depends entirely on your ultimate goal. Are you a company aiming to bring a new drug to market? An academic researcher exploring a scientific question? Or are you trying to provide a promising therapy to patients with a life-threatening illness? Each scenario requires a different type of IND. Choosing the right path from the start is crucial for a smooth regulatory process. Let’s walk through the main categories so you can identify which one fits your project.
Commercial IND
If your objective is to eventually sell your drug, the Commercial IND is the path for you. This is the most common type of application submitted by pharmaceutical and biotech companies. The entire process is built around the goal of commercialization—gathering the necessary data to prove the drug is safe and effective for its intended use and, ultimately, gaining marketing approval. When you fill out your application, you’ll need to check the “Commercial IND” box on FDA Form 1571. This signals to the FDA that your long-term plan includes bringing a new product to patients and providers, setting the stage for all future regulatory interactions and requirements.
Research IND
A Research IND, sometimes called a non-commercial IND, is used when the goal is purely scientific investigation. This type of application is typically submitted by individual physicians, academic institutions, or nonprofit organizations that have no intention of selling the drug. The focus is on answering a specific research question, such as exploring a drug’s mechanism of action or its effect on a particular disease. These studies are often smaller in scale and shorter in duration than commercial trials. The findings from a Research IND are usually intended for publication in scientific journals to contribute to the broader medical knowledge base, rather than to support a marketing application.
Treatment IND
A Treatment IND provides a pathway for patients with serious or immediately life-threatening conditions to gain access to experimental drugs that have shown promise in clinical trials. This option becomes available when a drug is in the later stages of development (Phase 2 or 3) but is not yet approved by the FDA. It’s a form of Expanded Access, also known as “compassionate use,” designed for situations where a patient has no comparable or satisfactory alternative treatment options. The purpose is to bridge the gap for critically ill patients, allowing them to receive a potentially life-saving therapy while the final regulatory review is still underway.
Emergency Use IND
The Emergency Use IND is designed for urgent, life-threatening situations where there is no time to submit a full IND application through the standard process. This allows a physician to use an unapproved drug or biologic to treat a single patient in an emergency. The FDA can authorize an Emergency Use IND over the phone, enabling treatment to begin immediately. It’s a critical mechanism for patients who don’t meet the criteria for an existing clinical trial and need immediate intervention. The formal application is then submitted to the FDA within a specified timeframe after the authorization is granted.
Choose the Right IND for Your Project
Selecting the correct IND type is a foundational step in your drug development journey. Your choice will influence everything from the scope of your preclinical data to the design of your clinical trials and your long-term compliance obligations. As a general rule, companies should begin developing a regulatory plan as soon as they have data suggesting a potential clinical benefit. This early planning ensures your strategy aligns with your goals, whether they are commercial, academic, or compassionate. Making the right choice upfront saves time, reduces the risk of regulatory hurdles, and sets a clear course for your project’s future.
The IND Review Process: What to Expect
Submitting your IND application is a huge milestone, but what happens next? The FDA’s review process can feel like a black box if you’re not prepared. Understanding the timeline and key decision points is crucial for keeping your project on track. Let’s walk through the key stages, from initial consultations to the final decision, so you know exactly what to expect and how to manage each step effectively.
Start with a Pre-IND Consultation
Before you even submit your application, you have the opportunity to meet with the FDA. Taking advantage of a pre-IND consultation is one of the smartest moves you can make. This meeting allows you to present your development plan and get direct feedback from the agency’s experts. It’s your chance to ask questions, clarify regulatory expectations, and make sure your submission is on the right track. This early dialogue can help you identify and address potential issues before they cause delays, ultimately streamlining your entire review process. Think of it as a strategy session that sets the foundation for a successful submission.
The Initial 30-Day Review Period
Once you submit your IND, the clock starts ticking. The FDA has an initial 30-day review period to conduct a thorough safety assessment of your application. Their primary goal is to ensure that the proposed clinical trial does not place human subjects at unreasonable risk. If the agency doesn’t contact you with any objections or place a clinical hold on your study within those 30 days, your IND automatically becomes effective. This means you have the green light to begin your clinical trials as outlined in your protocol. This initial review is a critical checkpoint for verifying that your proposed study meets all necessary safety and regulatory standards.
Address Key Safety Considerations
At the heart of your IND application is the safety of your trial participants. The FDA scrutinizes every detail to ensure you’ve done your due diligence. Your application must include robust preclinical data from laboratory and animal studies that demonstrate the drug is reasonably safe for initial human testing. You’ll also need to provide comprehensive information on your chemistry, manufacturing, and controls (CMC) to prove the product is consistent and stable. Finally, a detailed clinical trial protocol is required to show that your study is well-designed and minimizes potential risks. Providing clear and complete information in these areas is essential for building the FDA’s confidence in your product.
Understand the Clinical Hold Process
If the FDA identifies significant concerns during its 30-day review, it may place your study on a clinical hold. A clinical hold is an order from the agency to delay or suspend a proposed clinical trial. This isn’t a final rejection, but rather a pause until you resolve the specific issues the FDA has raised. Reasons for a hold can range from an incomplete application to concerns about the study design or the safety of the investigational drug. Understanding this process is critical. If you receive a clinical hold, you’ll need to work diligently to address the agency’s feedback and submit a complete response to have the hold lifted.
Manage Post-Submission Communications
After you submit your IND, you can expect to receive a confirmation letter from the FDA. For biologics, the Center for Biologics Evaluation and Research (CBER) will manage the review. Throughout the 30-day period, the review team will assess your submission to ensure it meets all regulatory requirements and that your proposed study is scientifically sound. It’s important to maintain an open line of communication and be prepared to respond to any questions or requests for additional information promptly. Clear and effective communication during this phase can help you address potential concerns quickly and keep the review process moving forward smoothly.
How to Meet Key Regulatory Requirements
Submitting an IND application is more than just presenting your scientific findings; it’s about demonstrating your commitment to a safe, ethical, and controlled development process. The FDA needs to see that you have robust systems in place to protect clinical trial participants and ensure the quality of your investigational drug. Think of these requirements as the foundation upon which your entire clinical program is built. Getting them right from the start is non-negotiable and sets the tone for your relationship with the agency.
Meeting these standards involves several key areas. You’ll need to show that your manufacturing processes are consistent and reliable, that an independent committee has reviewed your study for ethical concerns, and that every participant will be fully informed before they agree to join. It also means having quality control measures woven into every step of your operations. For companies with an eye on global markets, it’s also wise to consider how your program aligns with international standards. Let’s walk through what each of these requirements entails so you can build a compliance framework that supports a successful application.
Good Manufacturing Practices (GMP)
Good Manufacturing Practices (GMP) are the FDA’s minimum standards for how drugs are made, processed, and packaged. For your IND, this means proving your investigational drug can be produced consistently and free of contamination. This is primarily addressed in the Chemistry, Manufacturing, and Controls (CMC) section of your application. You need to provide detailed documentation showing that the drug used in your clinical trials will be the same from batch to batch. The FDA wants assurance that any results you see in your studies are due to the drug itself, not variations in its production. This involves documenting everything from raw material sourcing to final product testing, ensuring every step is controlled and repeatable. You can find the FDA’s official regulations for GMP on their website.
Institutional Review Board (IRB) Requirements
Before you can enroll a single participant in your study, your clinical protocol must be reviewed and approved by an Institutional Review Board (IRB). An IRB is an independent committee made up of scientific and non-scientific members whose primary job is to protect the rights and welfare of human research subjects. Your IND application must include a commitment that you will secure IRB approval at each clinical site. The board will scrutinize your study design, recruitment materials, and informed consent documents to ensure the trial is ethical and that risks to participants are minimized. The FDA sees the IRB as a critical partner in overseeing clinical investigations, and their approval is a mandatory step before your study can begin.
Informed Consent Documentation
Informed consent is a cornerstone of ethical clinical research. It’s the process of ensuring potential participants have all the information they need to make a voluntary decision about joining a study. Your IND application must include the informed consent form you plan to use. This document needs to clearly explain the study’s purpose, procedures, potential risks, and potential benefits in language that is easy to understand. It must also state that participation is voluntary and that the individual can withdraw at any time without penalty. The FDA reviews this document carefully to ensure it is not coercive and provides a complete picture of what participation entails. This process is fundamental to respecting the autonomy and protecting human subjects in research.
Quality Control Measures
Beyond GMP, the FDA expects you to have comprehensive quality control measures integrated into your entire development program. This means having systems in place to ensure the integrity and reliability of all the data you collect, from preclinical lab results to clinical trial observations. Strong quality control demonstrates that your operations are well-managed and that your results are trustworthy. For smaller companies, discussing your quality systems during a pre-IND meeting can be incredibly valuable. It gives you a chance to get direct FDA feedback on your plans and make adjustments before you formally submit your application. A robust quality management system shows the agency you are serious about producing reliable data and a safe product.
International Considerations
While your IND application is for the US, drug development is often a global endeavor. If you plan to run trials or eventually market your drug in other countries, it’s smart to think about international regulatory standards from the beginning. Major regulatory bodies like the European Medicines Agency (EMA) and Health Canada have their own requirements for authorizing clinical trials. By understanding these different frameworks early, you can design a development program that meets multiple sets of standards. The International Council for Harmonisation (ICH) works to align technical requirements for pharmaceuticals, and following their guidelines can make it much easier to submit applications in different regions later on. This foresight can save you significant time and resources down the road.
Avoid These Common IND Application Pitfalls
Submitting an IND application is a major milestone, but the path is often filled with potential setbacks. A rejection or a clinical hold doesn’t just delay your timeline; it can be incredibly costly and demoralizing for your team. The good news is that many of the most common mistakes are entirely avoidable with the right preparation and foresight. By understanding where others have stumbled, you can create a clear path for your own application. Let’s walk through some of the most frequent pitfalls and how you can steer clear of them.
Documentation Management
Think of your IND application as the complete story of your drug. If that story is poorly written, disorganized, or has missing chapters, the FDA won’t have the confidence to let it proceed. One of the biggest challenges in IND submissions is the sheer volume of documentation required. It’s not enough to just have the data; you need to present it in a clear, compelling narrative. This means avoiding overly dense reports, ensuring every section is well-written, and providing just the right amount of information—too much data can be just as problematic as too little. A well-organized application shows the FDA you’re thorough and professional.
Manufacturing Control Issues
The FDA needs absolute certainty that the drug you plan to give to humans is the same one you tested in your nonclinical studies. This is where your Chemistry, Manufacturing, and Controls (CMC) section comes in. Inadequate CMC details are a frequent cause of a clinical hold, which stops your research in its tracks, delaying patient access to potentially vital treatments and adding significant costs to your development. You must clearly document your manufacturing process, quality control tests, and the stability of your drug product to prove it’s consistent, pure, and safe for human use. This isn’t the place to cut corners; meticulous detail is your best defense.
Safety Monitoring
At its core, the IND review is a safety check. The FDA’s primary goal is to protect human subjects. A common pitfall is failing to provide enough nonclinical data to convince reviewers that your product is reasonably safe for initial testing in humans. Determining exactly how much data is required can be tricky, but your pharmacology and toxicology studies must be robust. Beyond that, your application needs a detailed clinical protocol that outlines exactly how you will monitor participant safety, manage adverse events, and ensure the trial is conducted ethically and responsibly. Your plan must show you’ve thought through every potential safety concern.
Timeline Management
Developing a drug is a long-term project, and the regulatory process should be part of your strategy from the very beginning. Many companies make the mistake of treating the IND application as a final hurdle instead of an integrated part of the development plan. You should start thinking about your regulatory plan as soon as you have data suggesting a potential clinical benefit. This means mapping out your nonclinical studies, manufacturing timelines, and document preparation well in advance. A rushed application is often a sloppy one, so building a realistic timeline with built-in flexibility is key to a smooth submission process.
Resource Planning
Successfully preparing an IND application requires a significant investment of time, money, and expertise. Underestimating these resources is a recipe for trouble. You need a team that understands the science and the complex regulatory requirements. Many promising projects falter due to a lack of experience with the FDA’s expectations. Assembling the extensive documentation, managing nonclinical studies, and ensuring manufacturing compliance all demand specialized skills. Planning your budget and team structure early will help you identify any gaps you might need to fill with experienced regulatory consultants who can guide you through the process.
Your Toolkit for a Stronger Application
Putting together an IND application is a massive undertaking, but you don’t have to start from a blank page. A number of tools and resources are available to help you structure your submission, manage your documentation, and meet the FDA’s rigorous standards. Think of these as the essential components of your project management toolkit. By using them effectively, you can streamline your workflow, reduce the risk of common errors, and present a clear, comprehensive application to the agency. A well-organized submission not only makes a better first impression but also simplifies the review process for the FDA, which is always a good thing. Let’s walk through the key resources you should have on hand.
FDA Guidelines and Forms
Your first and most important stop should be the source itself: the FDA’s website. This is where you’ll find the official, up-to-date regulatory documents, instructions, and forms required for your IND submission. Spending time here is non-negotiable. Get familiar with the structure of the application and the specific information the agency expects for each section. The FDA provides comprehensive guidance documents that explain the requirements in detail. Downloading the correct forms, like Form FDA 1571 (the IND application cover sheet), directly from the source ensures you’re working with the current version and meeting all baseline requirements from the very beginning.
Development Toolkits
You don’t need to create your entire submission process from scratch. Many academic and research institutions have already developed roadmaps for the IND process and made them publicly available. These development toolkits often contain checklists, step-by-step instructions, and templates that can guide you through the complexities of the application. They are designed to translate dense regulatory requirements into a more manageable workflow. Using a well-structured toolkit can help you organize your research, track your progress, and ensure you haven’t missed any critical components before you submit your package to the FDA.
Quality Management Systems
An IND application involves an enormous amount of documentation, and keeping it all organized is a major challenge. This is where a robust Quality Management System (QMS) becomes essential. A QMS provides a structured framework for managing all your documents, data, and processes, ensuring everything is controlled, tracked, and compliant with regulatory standards. It helps you maintain data integrity, manage version control for documents, and create a clear audit trail. Implementing a Quality Management System isn’t just about good housekeeping; it’s a foundational element that demonstrates your commitment to quality and control, which can facilitate smoother interactions with the FDA.
Documentation Templates
To simplify the actual writing and compilation process, look for established documentation templates. Having a structured format for key documents like the IND initial application, cover letter, and Forms 1571 and 1572 can save you a significant amount of time and prevent simple mistakes. These templates ensure all the necessary information is included in the right place and presented clearly and professionally. Many organizations, including research universities, offer a compilation of IND resources that includes these valuable templates. Using them helps standardize your submission and ensures you’re following best practices from the start.
Set Your IND Application Up for Success
Submitting an IND application is a major milestone, but getting it right involves more than just filling out forms. A successful application is built on a foundation of careful planning, robust data, and clear communication. By focusing on a few key areas, you can significantly improve your chances of a smooth review process and avoid common delays. Think of it as building a strong case for your product from the very beginning.
Prepare a Clear and Complete Application
Your primary goal is to demonstrate that your product is reasonably safe for initial human testing. This requires collecting the right preclinical data and presenting it clearly. Incomplete or poorly organized applications are a common reason for clinical holds. Make sure every section is thorough, from your pharmacology and toxicology reports to your clinical protocols. The FDA reviewers need to follow your logic and understand your rationale without having to guess. A well-written, comprehensive submission shows that you are prepared and serious about your responsibilities as a sponsor.
Implement Strong Quality Control Systems
The FDA needs to see that you can consistently produce a quality product. This is where your Chemistry, Manufacturing, and Controls (CMC) information is critical. Your application must detail every step of your manufacturing and quality control processes for both the drug substance and the final drug product. This isn’t just about meeting a requirement; it’s about building confidence. Strong quality management systems show the FDA that you have control over your product’s identity, strength, quality, and purity, which is fundamental to patient safety.
Communicate Effectively with the FDA
Don’t wait until you submit your application to talk to the FDA. Requesting a pre-IND meeting is one of the most effective steps you can take, especially if you have limited regulatory experience. This meeting gives you a chance to get feedback on your plans, ask questions, and address potential concerns before they become official deficiencies. Building a transparent and professional relationship with the agency from the start can help make the entire review process more collaborative and efficient. It’s an opportunity to align your strategy with the FDA’s expectations.
Establish Safety Reporting Protocols
Before you even begin your clinical trials, you need a solid plan for monitoring and reporting adverse events. The FDA will expect you to have clear, established protocols for safety reporting. This includes defining what constitutes a serious adverse event, how data will be collected, and the timeline for reporting issues to the agency and Institutional Review Boards (IRBs). Having these systems in place demonstrates your commitment to participant safety and your ability to manage the responsibilities of a clinical trial sponsor. Proactive safety planning is non-negotiable.
Manage Your Ongoing Compliance
Receiving IND approval is not the end of your regulatory obligations; it’s the beginning. You will need to submit annual reports, amend your IND for any protocol changes, and maintain meticulous records. Ongoing compliance requires diligent documentation and a proactive approach to regulatory updates. Your team must be prepared to manage these long-term responsibilities to keep your project on track. Establishing a system for ongoing compliance management ensures that you can maintain your IND status and continue your development program without interruption.
Related Articles
- FDA IND Submission Process: A Step-by-Step Guide | J&J Compliance Consulting Group
- IND Submission Consulting: A Step-by-Step Guide | J&J Compliance Consulting Group
- Regulatory Compliance for Clinical Trials: A Practical Guide
Frequently Asked Questions
Is a pre-IND meeting with the FDA really necessary? While it’s not technically required, skipping a pre-IND meeting is a missed opportunity. Think of it as a strategy session where you get to align your plans with the agency’s expectations before you’ve invested all the time and resources into the final application. It’s your best chance to get direct feedback on your preclinical data, manufacturing plans, and clinical trial design, which can help you avoid major issues that could lead to a clinical hold later on.
What’s the single biggest mistake that causes a clinical hold? It often comes down to one of two things: insufficient safety data or weak manufacturing controls. The FDA’s primary job is to protect trial participants, so they scrutinize your preclinical toxicology studies to ensure the drug is reasonably safe to test in humans. Just as important is the Chemistry, Manufacturing, and Controls (CMC) section. If you can’t prove that you can produce a consistent, stable, and pure drug product for the trial, the FDA will put a stop to your study until you can.
What are my responsibilities after my IND is approved? Getting the green light from the FDA is just the beginning of your regulatory journey. Once your IND is active, you have ongoing obligations to keep the agency informed. This includes submitting annual progress reports, promptly reporting any serious or unexpected adverse events observed during your trials, and filing amendments to your IND any time you make significant changes to your clinical protocol or manufacturing process.
How is a Research IND different from a Commercial IND in practice? The main difference is the end goal. A Commercial IND is filed by a company that intends to eventually market the drug for sale, so every step is designed to gather data for a future marketing application. A Research IND, often filed by an academic investigator, is purely for scientific discovery. The goal is to answer a specific research question, not to commercialize a product, so the scope of the trials and the long-term regulatory requirements are typically less extensive.
Can I use data from studies conducted outside the U.S. in my IND application? Yes, and you absolutely must. The FDA requires a complete picture of all previous human experience with the investigational drug, regardless of where the studies were conducted. You need to provide a summary of this data, including any safety issues that were observed. Being transparent about all prior research helps the agency conduct a thorough risk assessment and make a fully informed decision about your proposed trial.